



July 15, 2021

Office of the Attorney General
State of Vermont

via email to: AGO.highcostprescriptiondrugs@vermont.gov

Pursuant to 18 V.S.A. §4637(c), Biogen is hereby providing additional information related to the 3-day notice of the introduction of a new prescription drug in the commercial market as submitted on June 17, 2021:

NDC	Description	Date Commercially Available	Wholesale Acquisition Cost (WAC)*
64406-0101-01	ADUHELM is supplied one vial per carton as follows: 170 mg/1.7 mL (100 mg/mL) single-dose vial	06/15/2021	\$952.00
64406-0102-02	ADUHELM is supplied one vial per carton as follows: 300 mg/3 mL (100 mg/mL) single-dose vial	06/15/2021	\$1,680.00

**Price to wholesalers, without regard to prompt pay or other discounts, rebates, chargebacks, or any fees paid to wholesalers for services performed. Does not represent prices charged to other customers or classes of trade.*

Additional information:

Requested Information	Biogen Submission
<p><i>A description of the marketing and pricing plans used in the launch of the new drug in the United States and Internationally</i></p>	<p>ADUHELM will be marketed to Healthcare Professionals, Patients, Payers, and other appropriate audiences</p> <p>[Biogen has] engaged extensively with health economists, public health experts, and payers about ADUHELM – and we have examined other recent biologic drug innovations. Consistent with our pricing principles, we have established a price for ADUHELM that reflects the overall value this treatment brings to patients, caregivers and society – and one that will enable continuous innovation. We have determined the launch price of ADUHELM based on our belief in the impact of treatment as well as the size of the appropriate patient population based on the entry criteria of our clinical trials. Biogen has established the price of ADUHELM based on the overall value this treatment is expected to bring to patients, caregivers, and society, while reflecting key principles such as innovation, access and sustainability. The wholesale acquisition cost (WAC) of ADUHELM, which is an infusion once every four weeks, is \$4,312 per infusion for a patient of 74 kg—the average weight of a U.S. patient with mild cognitive impairment (MCI) or mild dementia. The yearly cost at the maintenance dose (10 mg/kg) would be \$56,000. The cost during the first year of treatment will be lower due to the titration period. WAC is a list price and not the net price or the price paid by patients with insurance.</p> <p>Biogen has a set of Pricing Principles that inform pricing decisions for its products. Those principles are: 1. Value to Patients, 2. Present and Future Benefit to Society, 3. Fulfilling our commitment to Innovation, 4. Evolution toward Value Based Care, and 5. Affordability & Sustainability.</p> <p>Further information can be found at: https://www.biogen.com/content/dam/corporate/en_us/pdfs/BIOGEN_PricingPrinciplesInfographic_4-26-19.pdf</p>
<p><i>The estimated volume of patients who may be prescribed the drug</i></p>	<p><u>2 Million</u></p> <p>Based on the entry criteria of the clinical trials conducted with ADUHELM, we estimate the appropriate patient population for ADUHELM to be approximately 1 - 2 million. These are patients who have been clinically diagnosed with mild cognitive impairment or mild dementia suspected to be due to Alzheimer’s disease who would have confirmed amyloid beta pathology, if tested. It is important to note that we do not expect all of these patients will be treated with ADUHELM, for a variety of reasons, including appropriate patient selection criteria, a complex diagnostic and care pathway and limited capacity of specialists, who we believe will be the primary prescribers of ADUHELM. As a result of these factors, we anticipate that patient uptake will be gradual over a number of years.</p>

Requested Information	Biogen Submission
<i>Whether the drug was granted breakthrough therapy designation or priority review by the FDA prior to final approval</i>	<p>ADUHELM <u>was not</u> granted breakthrough therapy designation.</p> <p>ADUHELM <u>was</u> granted priority review.</p>
<i>The date and price of acquisition if the drug was not developed by the manufacturer</i>	[N/A]

Please let me know if you need any additional information.

Best Regards,

Chris Cheney

Associate Director, Contracts & Pricing Governance

Biogen | 133 Boston Post Road, 17-308 | Weston, MA | 02493

Email: chris.cheney@biogen.com | Direct: 781 464 5876